Search

Your search keyword '"Lacroix-Triki, M."' showing total 257 results

Search Constraints

Start Over You searched for: Author "Lacroix-Triki, M." Remove constraint Author: "Lacroix-Triki, M."
257 results on '"Lacroix-Triki, M."'

Search Results

3. Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trial

4. Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort

5. 189O A phase II study of patritumab deruxtecan (HER3-DXd), in patients (pts) with advanced breast cancer (ABC), with biomarker analysis to characterize response to therapy (ICARUS-BREAST01)

6. 121TiP LESS: Single-arm study to de-escalate adjuvant endocrine therapy duration in post-menopausal women with HR+ HER2- early breast cancer at very low risk of metastasis

8. Deep Learning Allows Assessment of Risk of Metastatic Relapse from Invasive Breast Cancer Histological Slides

10. LBA72 Unraveling the mechanism of action and resistance to trastuzumab deruxtecan (T-DXd): Biomarker analyses from patients from DAISY trial

12. 340O Efficacy, safety and biomarker analysis of ICARUS-BREAST01: A phase II study of patritumab deruxtecan (HER3-DXd) in patients (pts) with HR+/HER2- advanced breast cancer (ABC)

13. Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer

14. 18P Comparative genomic profiling of primary and locally recurrent luminal breast cancers (BC)

15. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

17. 159P SiMosein, a real-life prospective evaluation of EndoPredict use in early ER-positive, HER2-negative breast cancers

18. 1124O Prediction of distant relapse in patients with invasive breast cancer from deep learning models applied to digital pathology slides

19. Interobserver variability in the assessment of stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative invasive breast carcinoma influences the association with pathological complete response: the IVITA study

20. Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer

21. Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials

22. Interobserver variability in upfront dichotomous histopathological assessment of ductal carcinoma in situ of the breast: the DCISion study

23. Amélioration des pratiques en pathologie mammaire : organisation régionale de relecture par télépathologie dans le cadre du groupe SENOPATH

25. 161O Randomized preoperative window of opportunity (WOO) study with the CDK4/6 inhibitor abemaciclib in early breast cancer (EBC) patients and differential gene expression pathway analyses with palbociclib

31. Abstract P4-08-23: EndoPredict prognostic signature in pN1mi, estrogen receptor-positive breast cancer: analysis of the French national registry for molecular signatures

32. Abstract P5-12-05: Phenotypic discordance between primary and metastatic breast cancer (MBC) in a large scale real-life multicentre French cohort

33. Abstract P3-11-10: Prosigna prognostic signature in pN1mi, estrogen receptor-positive breast cancer:the pN categorization impacts the BC risk stratification

34. First-in-human trial design for W0101: A first-in-class antibody-drug conjugate targeting IGF-1R and identification of the target patient population

35. Modulation of Rb phosphorylation and antiproliferative response to palbociclib: the preoperative-palbociclib (POP) randomized clinical trial

36. Abstract P1-07-07: Overtime distribution and predictors of local recurrences (LRs) in patients with hormone receptor positive (HR+) and node positive (N+) breast cancers (BCs): 10 -year follow-up analysis of UNICANCER-PACS 01 and PACS04 trials

37. Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.

38. Bridge The Distance Between Breast Pathologists: When The Senopath Network Opens Up To The Telepathology : SY02.01 | Telepathology

39. Does a very low dose of chronic I[superscript three]-irradiation induce a neuron loss in mice?

40. Abstract P6-09-05: Prognostic and predictive values of high endothelial venules (HEV) and tumor infiltrating CD8+ lymphocytes (CD8) in tumors of patients included in the adjuvant PACS04 trial: HEV is predictive of outcome for HER2+ tumors exposed to trastuzumab

41. Abstract P1-12-06: UCBG intergroup: 3-years efficacy results of the Unicancer-PACS08 trial including poor prognosis patients treated with docetaxel or ixabepilone in adjuvant setting

42. Identification of a Circulating MicroRNA Profile as a Biomarker of Metastatic Cutaneous Melanoma

43. Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification

45. Molecular evidence in support of the neoplastic and precursor nature of microglandular adenosis

48. ASTER 70s UNICANCER phase III Trial: Can a genomic prognosticator help tailoring adjuvant systemic treatment for luminal breast carcinoma in elderly women?

50. Prediction of Recurrence with the Recurrence Score in Pre- and Post-Menopausal Patients from the Pacs01 Trial

Catalog

Books, media, physical & digital resources